
Metro-Goldwyn-Mayer held an investor call the other day. But the home studio to James Bond had almost nothing to say about its prized property.
Naturally, the blog has questions.
What was the context of what MGM did have to say about No Time to Die?
Essentially listing it among various films either awaiting release or in production. Others included Respect, a “biopic” with Jennifer Hudson portraying Aretha Franklin and a sequel to a recent animated Addams Family movie.
MGM executives said its film slate, coupled with its TV business would mean good financial results in the second half of 2021 and going into 2022.
Is that all?
Pretty much.
What is up with that?
Strictly a guess: MGM is trying to project an image of a strong operation where everything is under control. In the past year there have been reports that MGM is seeking a buyer and that the studio explored licensing No Time to Die to streaming services before deciding not to proceed.
Some of the reports indicate that leaders of Danjaq/Eon weren’t initially informed of such discussions and weren’t happy.
From the perspective of a Bond fan, how useful are these investor calls?
Mixed at best. Occasionally, investors ask MGM executives about Bond film projects and if there are any ways MGM can get more out of the franchise. At times, that generates additional comments. But much of the time, MGM executives stick to talking points.
If there was any surprise about this week’s investor call, it’s MGM didn’t even do that. Just a quick mention that No Time to Die is in pipeline — something all Bond fans knew already.
Is there additional context to keep in mind?
No Time to Die’s costs are approaching $300 million. (The studio reportedly is incurring $1 million a month in interest costs for each month No Time to Die doesn’t come out.) MGM had been counting on a big theatrical release before the COVID-19 pandemic.
Filed under: James Bond Films | Tagged: Bond 25, Danjaq LLC, Eon Productions, Metro-Goldwyn-Mayer, No Time to Die, Respect, The Addams Family | Leave a comment »